Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • Cisplatin (A8321): DNA Crosslinking Agent for Chemotherap...

    2026-01-09

    Cisplatin (A8321): DNA Crosslinking Agent for Chemotherapy Resistance and Apoptosis Research

    Executive Summary: Cisplatin (CDDP) is a platinum-based chemotherapeutic compound that induces apoptosis by forming intra- and inter-strand DNA crosslinks, activating p53 and caspase signaling pathways (APExBIO, product page). It is extensively validated in cancer research for inducing apoptosis and inhibiting tumor growth in xenograft models (Jiang et al., 2024). Resistance to cisplatin, particularly in ovarian cancer, is linked to upregulation of DNA repair pathways such as BRCA1 phosphorylation via CLK2 kinase. Cisplatin generates oxidative stress through increased ROS production, contributing to ERK-dependent apoptosis (Cisplatin in Cancer Research: Unraveling Resistance Mechanisms). Solutions and stability require careful handling, as DMSO can inactivate the drug.

    Biological Rationale

    Cisplatin (CAS 15663-27-1), also known as CDDP, is a widely used chemotherapeutic compound with a molecular weight of 300.05 and formula Cl2H6N2Pt (APExBIO). Its clinical and preclinical significance stems from its ability to form covalent crosslinks with DNA guanine bases, causing structural DNA distortions and preventing replication and transcription. This triggers apoptosis, a key process for eliminating malignant cells. In ovarian and other cancers, platinum-based chemotherapy remains the first-line approach due to its broad-spectrum cytotoxicity (Jiang et al., 2024). However, resistance mechanisms—such as enhanced DNA repair—present ongoing challenges, highlighting the need for mechanistic studies using robust agents like cisplatin.

    Mechanism of Action of Cisplatin

    Cisplatin exerts its cytotoxic effect mainly by forming intra- and inter-strand crosslinks in DNA, predominantly at guanine N7 positions (APExBIO). These crosslinks cause replication fork stalling and block transcription. The DNA damage response engages p53, leading to activation of downstream caspase-3 and caspase-9, resulting in irreversible apoptosis (Cisplatin in Translational Oncology). In addition, cisplatin increases production of reactive oxygen species (ROS), promoting oxidative stress and activating ERK-dependent cell death pathways. These multifaceted mechanisms contribute to its reliability as a DNA crosslinking agent for apoptosis assays and tumor inhibition studies ( Cisplatin: DNA Crosslinking Agent for Mechanistic Cancer Research).

    Evidence & Benchmarks

    • Cisplatin forms covalent intra- and inter-strand crosslinks at DNA guanine N7, inhibiting DNA replication and transcription (Jiang et al., 2024, DOI:10.1002/mco2.537).
    • p53 is activated following DNA crosslinking, leading to caspase-3 and caspase-9 dependent apoptosis in cancer cells (Jiang et al., 2024, DOI:10.1002/mco2.537).
    • Cisplatin induces ROS generation, enhancing lipid peroxidation and promoting ERK-dependent apoptotic signaling (Cisplatin in Cancer Research).
    • In vivo, intravenous administration of cisplatin at 5 mg/kg on days 0 and 7 significantly inhibits tumor growth in xenograft models (Jiang et al., 2024).
    • Resistance to cisplatin in ovarian cancer is associated with upregulated CLK2 kinase activity, which phosphorylates BRCA1 at Ser1423 to enhance DNA repair (Jiang et al., 2024).
    • Experimental protocols recommend freshly preparing cisplatin solutions in DMF, as DMSO inactivates the compound (APExBIO).

    Applications, Limits & Misconceptions

    Cisplatin is extensively used for:

    • Apoptosis assays in cancer cell lines (e.g., ovarian, head and neck squamous cell carcinomas).
    • Tumor growth inhibition studies in xenograft animal models.
    • Investigation of chemotherapy resistance mechanisms, including p53 and BRCA1 signaling pathways.
    • Oxidative stress and ROS quantification research.

    For an in-depth guide on troubleshooting solubility and optimizing experimental workflows, see Cisplatin (SKU A8321): Real-World Solutions for Reliable Results; this article supplements those practical scenarios by detailing the molecular and resistance mechanisms in recent literature.

    Common Pitfalls or Misconceptions

    • Misconception: Cisplatin is soluble in water or ethanol.
      Fact: It is insoluble in both but soluble in DMF at ≥12.5 mg/mL (APExBIO).
    • Pitfall: Using DMSO as a solvent.
      Fact: DMSO inactivates cisplatin’s activity; DMF is recommended (APExBIO).
    • Misconception: Cisplatin solutions are stable for long-term storage.
      Fact: Solutions are unstable and should be freshly prepared; powder should be stored in the dark at room temperature.
    • Boundary: Cisplatin is not effective in all platinum-resistant tumors due to enhanced DNA repair mechanisms (e.g., BRCA1 phosphorylation by CLK2) (Jiang et al., 2024).
    • Pitfall: Assuming ROS induction is the only mechanism of apoptosis.
      Fact: Both DNA crosslinking and oxidative stress contribute to cell death, often in a context-dependent manner.

    For advanced insights into cisplatin’s immunomodulatory roles, see Cisplatin in Cancer Immunomodulation: Beyond DNA Crosslinking. Unlike that article, which focuses on immune regulation and PD-L1, this dossier emphasizes DNA damage and resistance pathways.

    Workflow Integration & Parameters

    • Preparation: Dissolve cisplatin in DMF (≥12.5 mg/mL). Use warming and ultrasonic treatment to improve solubility.
    • Stability: Store as a dry powder in the dark, at room temperature. Prepare solutions freshly before use.
    • In vivo dosing: For xenograft models, administer intravenously at 5 mg/kg on days 0 and 7 (Jiang et al., 2024).
    • Assays: Use for apoptosis induction, DNA damage quantification, and ROS measurement in cancer research.
    • Vendor selection: APExBIO’s Cisplatin (A8321) is validated for reproducibility and reliability in mechanistic and translational cancer studies (APExBIO).

    For troubleshooting and experimental decision trees, Cisplatin: DNA Crosslinking Agent for Mechanistic Cancer Research provides workflow diagrams; this dossier extends those guides by providing updated resistance and DNA repair insights.

    Conclusion & Outlook

    Cisplatin remains a benchmark chemotherapeutic and DNA crosslinking agent in cancer research, enabling definitive apoptosis, DNA damage, and xenograft inhibition studies. Its effectiveness is modulated by cellular DNA repair pathways, notably via BRCA1 phosphorylation by CLK2, underscoring the importance of mechanistic context in experimental design (Jiang et al., 2024). Ongoing research into resistance mechanisms and immunomodulatory roles will further expand cisplatin’s relevance. For authoritative sourcing and technical support, APExBIO’s Cisplatin (A8321) is a preferred choice for reproducibility and validated performance in cancer research workflows (APExBIO).